Objective: The current study prospectively investigated the relationship between cigarette use and the onset of, persistence of, and relapse to cannabis use disorder (CUD) 3 years later among adults in the United States.
Methods: Analyses included respondents who completed Waves 1 and 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (2001–2002 and 2004–2005, respectively) and responded to questions about cigarette use, cannabis use, and CUD (n = 34,653). CUDs were defined by DSM-IV criteria using the Alcohol Use Disorder and Associated Disabilities Interview Schedule–Diagnostic Version IV. Multivariable logistic regression models were used to calculate the odds of CUD onset, persistence, and relapse at Wave 2 by Wave 1 cigarette use status. Analyses were adjusted for sociodemographics, psychiatric disorders, nicotine dependence, and alcohol and other substance use disorders.
Results: Cigarette use at Wave 1 was associated with onset of CUD at Wave 2 among those without Wave 1 cannabis use (adjusted odds ratio [AOR] = 1.62; 95% CI, 1.35–1.94) but not among those with Wave 1 cannabis use (AOR = 1.00; 95% CI, 0.83–1.19). Cigarette use at Wave 1 was also associated with persistence of CUD at Wave 2 among those with CUD at Wave 1 (AOR = 1.63; 95% CI, 1.30–2.00) and relapse to CUD at Wave 2 among those with remitted CUD at Wave 1 (AOR = 1.23; 95% CI, 1.09–1.45).
Conclusions: Among adults, cigarette use is associated with increased onset and persistence of and relapse to CUD 3 years later. Additional attention to cigarette use in community prevention and clinical treatment efforts aimed at reducing CUD may be warranted.
Continue Reading...
Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70. PubMedCrossRef
Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1564–1574. PubMedCrossRef
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition (DSM-V). Washington, DC: American Psychiatric Association; 2013.
Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015;72(12):1235–1242. PubMedCrossRef
Hasin DS, Shmulewitz D, Sarvet AL. Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings. Am J Drug Alcohol Abuse. 2019;45(6):623–643. PubMedCrossRef
Grucza RA, Agrawal A, Krauss MJ, et al. Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry. 2016;73(3):300–301. PubMedCrossRef
Santaella-Tenorio J, Levy NS, Segura LE, et al. Cannabis use disorder among people using cannabis daily/almost daily in the United States, 2002-2016. Drug Alcohol Depend. 2019;205:107621. PubMedCrossRef
Campbell CI, Bahorik AL, Kline-Simon AH, et al. The role of marijuana use disorder in predicting emergency department and inpatient encounters: a retrospective cohort study. Drug Alcohol Depend. 2017;178:170–175. PubMedCrossRef
Compton WM, Gfroerer J, Conway KP, et al. Unemployment and substance outcomes in the United States 2002–2010. Drug Alcohol Depend. 2014;142:350–353. PubMedCrossRef
Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292–297. PubMedCrossRef
Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–328. PubMedCrossRef
Ecker AH, Lang B, Hogan J, et al. Cannabis use disorder among veterans: comorbidity and mental health treatment utilization. J Subst Abuse Treat. 2020;109:46–49. PubMedCrossRef
Flórez-Salamanca L, Secades-Villa R, Budney AJ, et al. Probability and predictors of cannabis use disorders relapse: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2013;132(1–2):127–133. PubMedCrossRef
Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. Addiction. 2012;107(7):1221–1233. PubMedCrossRef
Rabin RA, George TP. A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use. Am J Addict. 2015;24(2):105–116. PubMedCrossRef
Goodwin RD, Pacek LR, Copeland J, et al. Trends in daily cannabis use among cigarette smokers: United States, 2002–2014. Am J Public Health. 2018;108(1):137–142. PubMedCrossRef
Weinberger AH, Pacek LR, Wall MM, et al. Trends in cannabis use disorder by cigarette smoking status in the United States, 2002–2016. Drug Alcohol Depend. 2018;191:45–51. PubMedCrossRef
US Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389(10082):1885–1906. PubMedCrossRef
Peters EN, Budney AJ, Carroll KM. Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. Addiction. 2012;107(8):1404–1417. PubMedCrossRef
Subramaniam P, McGlade E, Yurgelun-Todd D. Comorbid cannabis and tobacco use in adolescents and adults. Curr Addict Rep. 2016;3(2):182–188. PubMedCrossRef
Meier E, Hatsukami DK. A review of the additive health risk of cannabis and tobacco co-use. Drug Alcohol Depend. 2016;166:6–12. PubMedCrossRef
Agrawal A, Lynskey MT, Madden PA, et al. Simultaneous cannabis and tobacco use and cannabis-related outcomes in young women. Drug Alcohol Depend. 2009;101(1-2):8–12. PubMedCrossRef
Hindocha C, Shaban ND, Freeman TP, et al. Associations between cigarette smoking and cannabis dependence: a longitudinal study of young cannabis users in the United Kingdom. Drug Alcohol Depend. 2015;148:165–171. PubMedCrossRef
Montgomery L. Marijuana and tobacco use and co-use among African Americans: results from the 2013, National Survey on Drug Use and Health. Addict Behav. 2015;51:18–23. PubMedCrossRef
Behrendt S, Beesdo-Baum K, Höfler M, et al. The relevance of age at first alcohol and nicotine use for initiation of cannabis use and progression to cannabis use disorders. Drug Alcohol Depend. 2012;123(1-3):48–56. PubMedCrossRef
Lewinsohn PM, Rohde P, Brown RA. Level of current and past adolescent cigarette smoking as predictors of future substance use disorders in young adulthood. Addiction. 1999;94(6):913–921. PubMedCrossRef
Dierker L, Braymiller J, Rose J, et al. Nicotine dependence predicts cannabis use disorder symptoms among adolescents and young adults. Drug Alcohol Depend. 2018;187:212–220. PubMedCrossRef
Fairman BJ, Furr-Holden CD, Johnson RM. When marijuana is used before cigarettes or alcohol: demographic predictors and associations with heavy use, cannabis use disorder, and other drug-related outcomes. Prev Sci. 2019;20(2):225–233. PubMedCrossRef
Maxwell JC, Mendelson B. What do we know now about the impact of the laws related to marijuana? J Addict Med. 2016;10(1):3–12. PubMedCrossRef
Shi Y, Lenzi M, An R. Cannabis liberalization and adolescent cannabis use: a cross-national study in 38 countries. PLoS One. 2015;10(11):e0143562. PubMedCrossRef
Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 2018;43(1):195–212. PubMedCrossRef
Grant BF, Moore TC, Shepard J, et al. Source and Accuracy Statement: Wave 1 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2003.
Grant BF, Kaplan KD. Source and Accuracy Statement: The Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 2005.
Grant BF, Dawson DA, Hasin DS. The Alcohol Use Disorder and Associated Disabilities Interview Schedule–DSM-IV Version. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2001.
Grant BF, Harford TC, Dawson DA, et al. The Alcohol Use Disorder and Associated Disabilities Interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Drug Alcohol Depend. 1995;39(1):37–44. PubMedCrossRef
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
Creamer MR, Wang TW, Babb S, et al. Tobacco product use and cessation indicators among adults - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(45):1013–1019. PubMedCrossRef
Weinberger AH, Funk AP, Goodwin RD. A review of epidemiologic research on smoking behavior among persons with alcohol and illicit substance use disorders. Prev Med. 2016;92:148–159. PubMedCrossRef
Smith PH, Mazure CM, McKee SA. Smoking and mental illness in the US population. Tob Control. 2014;23(e2):e147–e153. PubMedCrossRef
Hines LA, Morley KI, Strang J, et al. Onset of opportunity to use cannabis and progression from opportunity to dependence: are influences consistent across transitions? Drug Alcohol Depend. 2016;160:57–64. PubMedCrossRef
van der Pol P, Liebregts N, de Graaf R, et al. Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug Alcohol Depend. 2013;133(2):352–359. PubMedCrossRef
Butterworth P, Slade T, Degenhardt L. Factors associated with the timing and onset of cannabis use and cannabis use disorder: results from the 2007 Australian National Survey of Mental Health and Well-Being. Drug Alcohol Rev. 2014;33(5):555–564. PubMedCrossRef
Braveman PA, Egerter SA, Mockenhaupt RE. Broadening the focus: the need to address the social determinants of health. Am J Prev Med. 2011;40(suppl 1):S4–S18. PubMedCrossRef
Lemyre A, Poliakova N, Bélanger RE. The relationship between tobacco and cannabis use: a review. Subst Use Misuse. 2019;54(1):130–145. PubMedCrossRef
Schauer GL, Rosenberry ZR, Peters EN. Marijuana and tobacco co-administration in blunts, spliffs, and mulled cigarettes: a systematic literature review. Addict Behav. 2017;64:200–211. PubMedCrossRef
Ream GL, Benoit E, Johnson BD, et al. Smoking tobacco along with marijuana increases symptoms of cannabis dependence. Drug Alcohol Depend. 2008;95(3):199–208. PubMedCrossRef
Fairman BJ. Cannabis problem experiences among users of the tobacco-cannabis combination known as blunts. Drug Alcohol Depend. 2015;150:77–84. PubMedCrossRef
Giroud C, de Cesare M, Berthet A, et al. E-Cigarettes: a review of new trends in cannabis use. Int J Environ Res Public Health. 2015;12(8):9988–10008. PubMedCrossRef
Haney M, Bedi G, Cooper ZD, et al. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry. 2013;73(3):242–248. PubMedCrossRef
Hill KP, Toto LH, Lukas SE, et al. Cognitive behavioral therapy and the nicotine transdermal patch for dual nicotine and cannabis dependence: a pilot study. Am J Addict. 2013;22(3):233–238. PubMedCrossRef
Lee DC, Budney AJ, Brunette MF, et al. Treatment models for targeting tobacco use during treatment for cannabis use disorder: case series. Addict Behav. 2014;39(8):1224–1230. PubMedCrossRef
Lee DC, Budney AJ, Brunette MF, et al. Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use. Drug Alcohol Depend. 2015;155:134–140. PubMedCrossRef
Lee DC, Walker DD, Hughes JR, et al. Sequential and simultaneous treatment approaches to cannabis use disorder and tobacco use. J Subst Abuse Treat. 2019;98:39–46. PubMedCrossRef
Becker J, Haug S, Kraemer T, et al. Feasibility of a group cessation program for co-smokers of cannabis and tobacco. Drug Alcohol Rev. 2015;34(4):418–426. PubMedCrossRef
Becker J, Haug S, Sullivan R, et al. Effectiveness of different Web-based interventions to prepare co-smokers of cigarettes and cannabis for double cessation: a three-arm randomized controlled trial. J Med Internet Res. 2014;16(12):e273. PubMedCrossRef
Becker J, Hungerbuehler I, Berg O, et al. Development of an integrative cessation program for co-smokers of cigarettes and cannabis: demand analysis, program description, and acceptability. Subst Abuse Treat Prev Policy. 2013;8(1):33. PubMedCrossRef
Connor Gorber S, Schofield-Hurwitz S, Hardt J, et al. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res. 2009;11(1):12–24. PubMedCrossRef
Fendrich M, Johnson TP, Wislar JS, et al. The utility of drug testing in epidemiological research: results from a general population survey. Addiction. 2004;99(2):197–208. PubMedCrossRef
US Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2016.
Tucker JS, Pedersen ER, Seelam R, et al. Types of cannabis and tobacco/nicotine co-use and associated outcomes in young adulthood. Psychol Addict Behav. 2019;33(4):401–411. PubMedCrossRef
Zhu SH, Sun JY, Bonnevie E, et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control. 2014;23(suppl 3):iii3–iii9. PubMedCrossRef
Connolly GN, Alpert HR, Wayne GF, et al. Trends in nicotine yield in smoke and its relationship with design characteristics among popular US cigarette brands, 1997–2005. Tob Control. 2007;16(5):e5. PubMedCrossRef
Land T, Keithly L, Kane K, et al. Recent increases in efficiency in cigarette nicotine delivery: implications for tobacco control. Nicotine Tob Res. 2014;16(6):753–758. PubMedCrossRef
Freeman TP, Craft S, Wilson J, et al. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction. 2021;116(5):1000–1010 PubMed
Arterberry BJ, Treloar Padovano H, Foster KT, et al. Higher average potency across the United States is associated with progression to first cannabis use disorder symptom. Drug Alcohol Depend. 2019;195:186–192. PubMedCrossRef
Schoenborn CA, Adams PF, Peregoy JA. Health behaviors of adults: United States, 2008–2010. Vital Health Stat 10. 2013;10(257):1–184. PubMed
Lantz PM. Smoking on the rise among young adults: implications for research and policy. Tob Control. 2003;12(suppl 1):i60–i70. PubMedCrossRef